Acute Coronary Syndromes: State-of-the-Art Diagnosis, Management, and Secondary Prevention
Journal of Clinical Medicine · 19.12.2025 · 15 (1) · 16
DOI: 10.3390/jcm15010016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.12.2025. Verfasst von Xun Yuan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Trust Foundation, London SW3 6NP, UK. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background: Acute coronary syndromes (ACSs) remain a leading cause of death and disability. Since the publication of the 2023 ESC ACS guidelines, multiple studies and an ESC/EAS dyslipidaemia update have refined how clinicians diagnose, revascularize, and treat ACS across the care continuum. Content: This state-of-the-art review synthesizes advances from 2023 to 2025 across five domains. Diagnosis: High-sensitivity troponin-based accelerated pathways remain foundational; GRACE 3.0 improves calibration for early vs. delayed angiography, while selective use of CCTA and routine use of intracoronary imaging/physiology help define the mechanism and optimize PCI. Revascularization: complete revascularization continues to underpin care in multivessel disease, with recent data favouring culprit-only PCI acutely and staged non-culprit treatment during the index stay in most STEMI presentations, particularly with heart-failure physiology. Antithrombotic therapy: Aspirin remains critical early after ACS-PCI; emerging evidence supports shorter DAPT and aspirin withdrawal after 1 month in carefully selected, low-ischaemic-risk patients, whereas day-0 aspirin-free strategies in unselected ACS are not non-inferior. Secondary prevention: A “strike early and strong” approach to LDL-cholesterol—often with combination therapy in hospital—is emphasized, alongside nuanced roles for SGLT2 inhibitors and GLP-1 receptor agonists. Special populations and implementation: Sex- and age-aware tailoring (including MINOCA/SCAD evaluation), pragmatic bleeding-risk mitigation, digitally enabled cardiac rehabilitation, and registry-driven quality improvement translate evidence into practice. Summary: Contemporary ACS care is moving from uniform protocols toward risk-stratified, mechanism-informed pathways. We offer practical algorithms and checklists to align interventional timing, antithrombotic intensity/duration, and secondary prevention with individual patient risk—bridging new evidence to bedside decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Trust Foundation, London SW3 6NP, UK.
- Department of Cardiology, Milton Keynes University Hospital, Milton Keynes MK6 5LD, UK.
- Department of Cardiology, Heart Centre Cologne, Faculty of Medicine and University Hospital, University of Cologne, 50937 Cologne, Germany.
- Department of Cardiology, University Hospital Heidelberg-Campus Mannheim, 69120 Mannheim, Germany.
ORCID-Profile: Xun Yuan, Stephan Nienaber, Ibrahim Akin
Zitieren
APA
Yuan, X., Nienaber, S., Akin, I., Kabir, T., & Nienaber, C. A. (2025). Acute Coronary Syndromes: State-of-the-Art Diagnosis, Management, and Secondary Prevention. Journal of Clinical Medicine, 15(1), 16. https://doi.org/10.3390/jcm15010016
Vancouver
Yuan X, Nienaber S, Akin I, Kabir T, Nienaber CA. Acute Coronary Syndromes: State-of-the-Art Diagnosis, Management, and Secondary Prevention. Journal of Clinical Medicine. 2025;15(1):16. doi:10.3390/jcm15010016
BibTeX
@article{Yuan2025,
author = {Yuan, Xun and Nienaber, Stephan and Akin, Ibrahim and Kabir, Tito and Nienaber, Christoph A},
title = {Acute Coronary Syndromes: State-of-the-Art Diagnosis, Management, and Secondary Prevention},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {15},
number = {1},
pages = {16},
doi = {10.3390/jcm15010016}
}
EUVIMED